Contemporary Approaches to Adrenocortical Carcinoma

Adrenocortical carcinoma is a rare, aggressive cancer with a poor prognosis. Management of early-stage disease relies on surgical resection, which remains the only potentially curative therapy. Open surgery remains the standard of care, with minimally invasive approaches being appropriate in cases with smaller tumors and no evidence of local invasion. Advanced disease traditionally relies on mitotane-based chemotherapies to control disease progression. Clinical trials evaluating the potential efficacy of immunotherapy, checkpoint inhibitors, and tyrosine kinase inhibitors are ongoing but have yet to yield results that impact guideline-based therapies. Other therapies, such as radiation, are commonly used for recurrent or metastatic disease.

Authors

Institutions

Publication Details

Journal
Advances in Oncology
Published
2024-12-24
DOI
https://doi.org/10.1016/j.yao.2024.11.003
Citations
1
Primary Topic
Adrenal and Paraganglionic Tumors
Type
article
Field-Weighted Citation Impact
0.57
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Contemporary Approaches to Adrenocortical Carcinoma

Alexandria D. McDow, Hadley E. Ritter, Anthony D. Yang, Alexa J. Hughes
1 citations
Advances in Oncology
Adrenal and Paraganglionic Tumors
0.57
article

Contemporary Approaches to Adrenocortical Carcinoma

Alexandria D. McDow, Hadley E. Ritter, Anthony D. Yang, Alexa J. Hughes
article en
1 citations

Abstract

Adrenocortical carcinoma is a rare, aggressive cancer with a poor prognosis. Management of early-stage disease relies on surgical resection, which remains the only potentially curative therapy. Open surgery remains the standard of care, with minimally invasive approaches being appropriate in cases with smaller tumors and no evidence of local invasion. Advanced disease traditionally relies on mitotane-based chemotherapies to control disease progression. Clinical trials evaluating the potential efficacy of immunotherapy, checkpoint inhibitors, and tyrosine kinase inhibitors are ongoing but have yet to yield results that impact guideline-based therapies. Other therapies, such as radiation, are commonly used for recurrent or metastatic disease.

Advances in OncologyVol. 5(1)
Indiana University – Purdue University Indianapolis (US)
Good health and well-being
Openalex Percentile: Top 26%
Adrenal and Paraganglionic Tumors
0.57
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.